MARKET

AGEN

AGEN

Agenus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.83
+0.26
+4.67%
After Hours: 5.81 -0.02 -0.34% 19:55 09/17 EDT
OPEN
6.01
PREV CLOSE
5.57
HIGH
6.04
LOW
5.52
VOLUME
6.89M
TURNOVER
--
52 WEEK HIGH
6.79
52 WEEK LOW
2.500
MARKET CAP
1.36B
P/E (TTM)
-5.2165
1D
5D
1M
3M
1Y
5Y
Sector Update: Health Care Stocks Down to End Week
MT Newswires · 18h ago
LCID, SDC and ABCL among pre market gainers
Corvus Pharmaceuticals (NASDAQ:CRVS) +56%. Innate Pharma (NASDAQ:IPHA) +32% Monalizumab data from COAST trial presented at ESMO Congress 2021 Surface Oncology (NASDAQ:SURF) +14%. BeiGene (NASDAQ:BGNE) +13% on positive DKN-01 + tislelizumab data in gastroes...
Seekingalpha · 22h ago
Agenus' Combo Therapy Trial Shows Higher Responses In Cervical Cancer
Benzinga · 1d ago
Agenus Says Cervical Cancer Combination Therapy Shows 'High' Response Rates in Phase 2 Trial
MT Newswires · 1d ago
BRIEF-Agenus Inc Says Combination Of Balstilimab Plus Zalifrelimab Doubles Responses In 2L Cervical Cancer In Data To Be Presented At Esmo
reuters.com · 1d ago
Combination of Balstilimab Plus Zalifrelimab Doubles Responses in 2L Cervical Cancer in Data to Be Presented at ESMO
-- Objective response rate of 33% and median duration of response not reached with 19.4 months median follow-up in PD-L1+ tumors; expands benefit of anti-PD-1 alone
GlobeNewswire · 1d ago
Agenus Inc (AGEN) Chairman and CEO Garo H Armen Sold $533,696 of Shares
GuruFocus News · 3d ago
Insider Sell: Agenus
MT Newswires · 3d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AGEN. Analyze the recent business situations of Agenus through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AGEN stock price target is 10.00 with a high estimate of 12.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 190
Institutional Holdings: 117.15M
% Owned: 50.25%
Shares Outstanding: 233.11M
TypeInstitutionsShares
Increased
63
11.37M
New
23
3.10M
Decreased
33
14.45M
Sold Out
18
836.27K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Chairman/Chief Executive Officer/Co-Founder/Director
Garo Armen
President/Chief Operating Officer
Jennifer Buell
Chief Compliance Officer/Vice President/General Counsel/Secretary
Evan Kearns
Vice President - Finance
Christine Klaskin
Other
Steven Oday
Lead Director/Independent Director
Timothy Wright
Independent Director
Brian Corvese
Independent Director
Susan Hirsch
Independent Director
Allison Jeynes-Ellis
Independent Director
Wadih Jordan
Independent Director
Ulf Wiinberg
No Data
About AGEN
Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company's discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company's vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.

Webull offers kinds of Agenus Inc stock information, including NASDAQ:AGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AGEN stock methods without spending real money on the virtual paper trading platform.